Regeneron Pharmaceuticals Inc. and SillaJen Inc. announced a clinical and supply agreement for a phase Ib dose-escalation study in renal cell carcinoma.
In the absence of the federal funding, cancer research will be leaning on private funders. But few private funders have the freedom to ask fundamental questions—questions whose answers may not have an immediate clinical impact but can dramatically advance scientific knowledge.
